Prolia (denosumab)

BU demonstrates potent pharmacological activity against breast cancer bone metastasis by targeting SEC13 and suppressing tumor-induced osteoclast differentiation. This effect is mediated through inhibition of HMGB1 release and blockade of the TLR4/NF-κB signaling axis, leading to reduced osteoclast formation and inhibition of metastatic progression.

Current research has predominantly focused on the RANKL signaling pathway, leading to development of anti-RANKL therapeutics such as Denosumab, while OPG-specific therapeutics remain underdeveloped. Collectively, future research could investigate whether compartment-specific OPG levels could serve as a biomarker for CRC and predict responses to immunotherapeutics, alongside drug repurposing of existing anti-RANKL therapeutics, and non-pharmacological strategies targeting OPG.

Current therapies, such as bisphosphonates and denosumab, offer limited survival benefits and carry significant safety risks, highlighting the need for novel agents that effectively inhibit osteolytic progression...rLGR4-ECD effectively inhibits RANKL-induced osteoclastogenesis and reduces bone metastasis burden through specific suppression of osteoclast activity, leading to improved survival in a preclinical model. Its excellent efficacy and manufacturability support its potential as a novel therapeutic agent for bone metastatic disease.

This case underscores the value of liquid biopsy detected mutations in guiding targeted therapy. Clinical, biochemical, and radiological findings support the potential use of selective RET tyrosine kinase inhibitors for this rare mutation. Serum calcitonin serves as a reliable quantitative biomarker of therapeutic efficacy.

P4, N=102, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting

Serial monitoring of TRACP-5b may provide supplementary information for detecting BM progression in patients with NSCLC treated with osimertinib.

Moreover, DNB/BMP-2 significantly improved torsional stiffness and maximum compressive force versus either treatment alone (all P < 0.05). The findings demonstrate that systemic DNB combined with local BMP-2 rapidly promotes femoral metaphyseal bone regeneration in osteoporotic rats.

Pharmacological inhibition of CARM1 (TP-064) effectively suppressed osteoclastogenesis and bone metastasis in denosumab-resistant models. These findings revealed a targetable resistance mechanism and provided a clinically actionable strategy to overcome microenvironment-driven metastasis through dual targeting of tumor and bone niches.

This case illustrates herpes zoster reactivation during Pembrolizumab-based chemo-immunotherapy in metastatic NSCLC. It emphasizes the importance of systematically excluding infectious causes in new cutaneous eruptions under immunotherapy and supports multidisciplinary management. These findings also highlight the need to further explore VZV screening and vaccination strategies in cancer patients undergoing immunosuppressive treatments.

P4, N=54, Completed, Tuen Mun Hospital | Recruiting --> Completed

Giant cell tumor of bone (GCTB) is an intermediate bone neoplasm defined by recurrent H3F3A mutations and limited systemic treatment options beyond denosumab...Functionally, 3D culture generally reduced sensitivity to many agents while preserving compound-dependent vulnerabilities. These results establish culture dimensionality as a key determinant of therapeutic susceptibility in GCTB PDCs and support incorporating proteome-informed 3D models into translational pipelines to prioritize clinically relevant drug candidates and biomarkers.

She received first-line endocrine therapy (letrozole+ribociclib+goserelin) combined with denosumab. Breast cancer gastric metastasis diagnosis relies on medical history, gastroscopy, and immunohistochemistry (GATA3+, CK7+, CK20-). The combination regimen yielded favorable efficacy, providing clinical reference for similar rare cases.